Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer
Wenzhen Zhu,* Chongyang Ren,* Yulei Wang, Lingzhu Wen, Guochun Zhang, Ning Liao Department of Breast Cancer, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, Guangzhou, 510080, People’s Republic of China*These authors contributed equally to...
Main Authors: | Zhu W, Ren C, Wang Y, Wen L, Zhang G, Liao N |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-01-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/prevalence-of-esr1-mutation-in-chinese-er-positive-breast-cancer-peer-reviewed-article-OTT |
Similar Items
-
ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
by: Tomás Reinert, et al.
Published: (2020-04-01) -
Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients
by: Violette Allouchery, et al.
Published: (2018-05-01) -
The predictive ability of plasma ESR 1 mutations for the efficacy of endocrine therapy in hormone-receptor-positive advanced breast cancer
by: Du YF, et al.
Published: (2018-09-01) -
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models
by: Amir Bahreini, et al.
Published: (2017-05-01) -
Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
by: Takashi Takeshita, et al.
Published: (2017-11-01)